Difference between revisions of "ADBICA"
From Wiki Weed
(Created page with "ADBICA is a designer drug identified in synthetic cannabis blends in Japan in 2013. ADBICA had not previously been reported in the scientific literature prior to its sale...") |
|||
| Line 1: | Line 1: | ||
| − | ADBICA is a designer drug identified in [[synthetic cannabis]] blends in Japan in 2013. ADBICA had not previously been reported in the scientific literature prior to its sale as a component of synthetic cannabis blends. ADBICA features a carboxamide group at the 3-indole position, like [[SDB- | + | ADBICA is a designer drug identified in [[synthetic cannabis]] blends in Japan in 2013. ADBICA had not previously been reported in the scientific literature prior to its sale as a component of synthetic cannabis blends. ADBICA features a carboxamide group at the 3-indole position, like [[SDB-001]] and [[STS-135]]. The stereochemistry of the tert-butyl side-chain in the illicitly sold product is unresolved, though in a large series of indazole derivatives structurally similar to ADBICA that are disclosed in Pfizer patent WO 2009/106980, activity resides exclusively in the (S) enantiomers. Nothing is known of the pharmacological activity of ADBICA in humans or other animals. |
==See also== | ==See also== | ||
Latest revision as of 18:34, 14 February 2015
ADBICA is a designer drug identified in synthetic cannabis blends in Japan in 2013. ADBICA had not previously been reported in the scientific literature prior to its sale as a component of synthetic cannabis blends. ADBICA features a carboxamide group at the 3-indole position, like SDB-001 and STS-135. The stereochemistry of the tert-butyl side-chain in the illicitly sold product is unresolved, though in a large series of indazole derivatives structurally similar to ADBICA that are disclosed in Pfizer patent WO 2009/106980, activity resides exclusively in the (S) enantiomers. Nothing is known of the pharmacological activity of ADBICA in humans or other animals.
